The research by Franco et al. (2022) (52) on deviant MFN2 in Charcot-Marie-Tooth disease exhibits that pharmacological activators of Mitofusin-2 can repair mitochondrial function including reverse neurodegenerative upshot in vivo. This evidence concerns the gene MFN2 and Charcot-Marie-Tooth disease.